Home > Company Profiles > Nordic Pharma Corporate functions : Paris, France Amsterdam, Netherlands Year of incorporation : 1995 Number of employees : 460 Production Footprint : Farmaprim (Moldova) A focus on niche products means expertise in rheumatology, critical care and women’s health Nordic Group is a privately owned international pharmaceutical company with a presence in 17 countries. It focuses on the development and commercialisation of a wide variety of products to respond to unmet medical needs. Nordic Group expertise relies on the development and sales of its own products, but also on partner products acquired at various stages of development. Its portfolio of therapeutic areas includes rheumatology, women’s health and critical care. Strengths Nordic Pharma is a medium-size pharmaceutical company, with an impressive history of acquisitions and internal product development. It focuses on the development of many products in rheumatology, critical care and women’s health. Nordic Pharma has a wide reach across all Europe, with a presence in 17 countries. Nordic Pharma’s emphasis on rheumatology is exemplified by its ‘Nordimet Pen’, which treats rheumatism and arthritis. Nordimet Pen administers the drug Methotrexate safely, reliably, and above all, highly effectively. Nordimet Pen is a single dose auto-injector, which means that patients can administer it themselves without support from a nurse. Nordic Pharma also has a strong track record in women’s health. In this regard, one of its major products is Mifepristone, which combined with Misoprostol, allows for the safe and early termination of pregnancy. Mifepristone is also self-administered and has significant benefits when compared to surgical termination of pregnancy. Critical care is Nordic Pharma’s third, and fast developing, therapeutic area. Critical care encompasses oncology products such as Teysuno for the treatment of gastric cancer, cardiac surgery products such as Trasylol, as well as anaesthesiology and orphan drugs such as Amglidia for postnatal diabetes. Business type: B2C and B2B Pharmaceutical company which produces and commercializes both promoted products and generics Core treatment areas Rheumatology Haematology Gynaecology Oncology Anaesthesia Neonatal diabetes Capabilities: Development Manufacturing Commercial Registration / Safety Monitoring Market Access Life Cycle Management Technology Tablets, injections, creams, suppositories, ovules, medical devices Visit website Company commercial footprint Corporate functions Commercial footprint Manufacturing footprint Other company profiles Address SEVER Life Sciences BV Siriusdreef 41 2132 WT Hoofddorp The Netherlands Contact Phone +41 58 301 0102 E-mail info@severlifesciences.com © SEVER Life Sciences. All rights reserved.